Recognizing the Heterogenous Nature of Mantle Cell Lymphoma

Kami Maddocks, MD

January 19, 2023

Kami Maddocks, MD, reflects on the variability in treatment outcomes and toxicities in mantle cell lymphoma in comparison to other hematologic cancers. Overall, Dr Maddocks emphases that in a condition without a standard-of-care treatment, clinicians need to work to find the best approach for that particular patient scenario.

Dr Maddocks also emphasizes that it is important to communicate with patients that the treatment landscape has changed considerably and that what they find in their research in terms of median overall survival may not apply to their current situation.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Recognizing the Heterogenous Nature of Mantle Cell Lymphoma - Medscape - Jan 19, 2023.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

Recognizing the Heterogenous Nature of Mantle Cell Lymphoma

Tables

Authors and Disclosures

Authors and Disclosures

Expert

Kami Maddocks, MD

Comments

Email This

Feedback